Diurnal Limited   Report issue

For profit Phase 1 Phase 3
Founded: Cardiff United Kingdom (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2007
NCT00519818
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Diurnal Limited | Diurnal Ltd.

Active Ingredients

Drugs in Phase 3 Trials (3)

hydrocortisone (solu-cortef) (7 trials)

prednisone (meticorten) (1 trial)

urea (11 trials)

Drugs in Phase 1 Trials (1)

testosterone (delatestryl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenal Hyperplasia, Congenital (Phase 3)

Adrenal Insufficiency (Phase 3)

Adrenocortical Hyperfunction (Phase 3)

Adrenogenital Syndrome (Phase 3)

Endocrine System Diseases (Phase 2)

Hyperplasia (Phase 3)

Hypogonadism (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 4